Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03734029
Title Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo, Inc.
Indications

breast cancer

Therapies

Trastuzumab deruxtecan

Nab-paclitaxel

Capecitabine

Paclitaxel

Gemcitabine

Eribulin

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.